Hologic (HOLX) reported $1.02 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 0.9%. EPS of $1.03 for the same period compares to $0.98 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.02 billion, representing no surprise. The company delivered an EPS surprise of +0.98%, with the consensus EPS estimate being $1.02.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Hologic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Total Breast Health: $369.10 million versus $391.46 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.3% change.
- Revenue- GYN Surgical: $166.30 million compared to the $166.25 million average estimate based on four analysts. The reported number represents a change of +2.5% year over year.
- Revenue- Skeletal Health: $15.80 million versus $14.97 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -37.8% change.
- Revenue- Total Diagnostics: $470.60 million versus the four-analyst average estimate of $455.29 million. The reported number represents a year-over-year change of +5.1%.
- Revenues- Diagnostics- Cytology and Perinatal: $125.40 million compared to the $122.37 million average estimate based on three analysts. The reported number represents a change of +4.5% year over year.
- Revenues- Breast Health- Breast Imaging: $281.60 million versus $305.26 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -6.6% change.
- Revenues- Diagnostics- Blood Screening: $4.10 million versus the three-analyst average estimate of $4.99 million. The reported number represents a year-over-year change of -48.8%.
- Revenues- Diagnostics- Molecular Diagnostics: $341.10 million versus $330.68 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.7% change.
- Revenues- Breast Health- Interventional Breast Solutions: $87.50 million compared to the $85.02 million average estimate based on three analysts. The reported number represents a change of +14.7% year over year.
- Revenues- Service and other revenue: $203.90 million versus $191.73 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.
- Revenues- Product Sales: $817.90 million versus $847.57 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.2% change.
Shares of Hologic have returned -1.5% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Hologic, Inc. (HOLX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
